As for any degenerative disease, early diagnosis in prostate cancer is crucial to improve patients’ quality of life and reduce the mortality rate, which amounts to 350,000 deaths each year.
When prostate cancer is suspected, diagnosis must be confirmed by a biopsy and subsequent histological analysis. However, biopsy is far from being accurate, as its mostly manual nature causes a significant diagnostic error that may exceed 25%.
new cases
A single cart holding the robotic needle positioner and housing all the electronic components
The Robiopsy Project aims at evolving the robotic device for prostate cancer biopsy demonstrated during the ERC-PoC PROST into a product prototype that will be ready for clinical trials.
A multi-centric study will collect data for automatic prostate segmentation and lesion identification.
In parallel to the technical development, the project will analyse the business case of prostate biopsy in selected European Countries, and the time/cost reduction due to the new device.
We are happy to announce that the Robiopsy project was presented during the 17th SIHTA Società Italiana Health Technology Assessment national congress, which took place from 5 to 7 November…
Colleagues from the University Hospital Freiburg represented Robiopsy at the annual congress of the European Association of Urology in Paris (EAU 2024) at the beginning of April. Among many other urological…
Robiopsy team attended ERF 2024 from the 13th to the 15th of March, in Rimini (Italy). The project was present with a booth in the dedicated area: this was a…
Robiopsy consortium partners – ACMIT Gmbh – Austrian Center for Medical Innovation and Technology, Università degli Studi di Verona, Needleye Robotics Srl, Day One – met last week as part…
The company was founded by a group of researchers from
the University of Verona, leaded by Professor Paolo Fiorini and with an experience in the field of medical robotics of more than 15 years.
